White Brittany, Snyder Heather S, Patel Megan Van Berkel
Department of Pharmacy, Erlanger Health-System, Chattanooga, TN, USA.
Department of Internal Medicine, The University of Tennessee Health Science Center College of Medicine-Chattanooga, TN, USA.
J Pharm Pract. 2023 Feb;36(1):126-138. doi: 10.1177/08971900211017857. Epub 2021 Jun 7.
Poor sleep during hospitalization is common and implicated in worse patient outcomes. Despite implementation of non-pharmacologic techniques, medications are still frequently required. The study objective is to assess the frequency of new medications administered for sleep in hospitalized patients and to review literature evaluating these drug therapies in the inpatient setting.
This retrospective study included adult inpatients if they received a new medication for sleep during a 5-day period. Patients were excluded if the medication was continued from home or if sleep was not the documented indication. For the literature review, a MEDLINE search was conducted to identify studies pertaining to pharmacotherapy for sleep in hospitalized patients.
Of 1,968 patient-days reviewed, a medication for sleep was given for 166 patient-days (8.4%) in 78 patients. Melatonin was most commonly received (70.5%), followed by benzodiazepines (9.6%). A review of antihistamines, benzodiazepines, melatonin, quetiapine, trazodone, and Z-drugs (non-benzodiazepine hypnotics) was conducted and 23 studies were included.
Despite widespread use of pharmacotherapy for sleep, there is a paucity of data evaluating use in the inpatient setting. Although there is significant heterogeneity among studies, melatonin has the strongest evidence for use and is an attractive option given its lack of adverse reactions and drug interactions. Benzodiazepines and Z-drugs were also frequently utilized; however, their reduced clearance in the elderly and potential for compounded sedative effects should be weighed heavily against potential sleep benefits. Antipsychotic agents cannot be recommended for routine use due to limited data and the potential for significant adverse effects.
住院期间睡眠质量差很常见,且与更差的患者预后相关。尽管实施了非药物技术,但仍经常需要使用药物。本研究的目的是评估住院患者中用于睡眠的新药物的使用频率,并回顾评估这些药物疗法在住院环境中的文献。
这项回顾性研究纳入了在5天内接受用于睡眠的新药物的成年住院患者。如果药物是从家中延续使用的,或者睡眠不是记录的用药指征,则将患者排除。对于文献综述,进行了MEDLINE搜索,以识别与住院患者睡眠药物治疗相关的研究。
在审查的1968个患者日中,78名患者中有166个患者日(8.4%)接受了用于睡眠的药物。最常使用的是褪黑素(70.5%),其次是苯二氮䓬类药物(9.6%)。对组胺药、苯二氮䓬类药物、褪黑素、喹硫平、曲唑酮和Z类药物(非苯二氮䓬类催眠药)进行了综述,共纳入23项研究。
尽管药物疗法广泛用于睡眠,但评估其在住院环境中使用情况的数据却很匮乏。尽管研究之间存在显著异质性,但褪黑素使用的证据最为充分,且因其缺乏不良反应和药物相互作用,是一个有吸引力的选择。苯二氮䓬类药物和Z类药物也经常被使用;然而,应权衡它们在老年人中清除率降低以及潜在的复合镇静作用与潜在的睡眠益处。由于数据有限且存在显著不良反应的可能性,不建议常规使用抗精神病药物。